CMECNE

The Identification and Management of Immune-related Adverse Events in Patients with Cancer: Practice Essentials for Emergency Medicine Providers

The Identification and Management of Immune-related Adverse Events in Patients with Cancer: Practice Essentials for Emergency Medicine Providers

This activity is supported by an educational grant from Bristol-Myers Squibb.

Overview

Author(s)/Faculty: Jeffrey S. Weber, MD, PhD; Patricia Brock, MD; Rajni Kannan, BS, MS, RN, ANP-BC; Kathleen M. Madden, RN, MSN, FMP-BC, AOCMP, APHN-BC
Source: Healio - Hematology/Oncology Education Lab
Type: VideoArticles/Items: 3
Release Date: 3/21/2017Expiration Date: 3/20/2018
Credit Type: CNE / CMENumber of Credits: 1
Cost: FreeProvider: Vindico Medical Education
The incorporation of immunotherapies, especially the immune checkpoint inhibitors, into treatment regimens for patients with cancer, have significantly improved clinical outcomes in these patient populations.  The utilization of immune checkpoint inhibitors in cancer therapy are associated with unique immune-related adverse events (irAEs), most commonly manifesting in the skin, gastrointestinal tract, and endocrine system. Patients presenting with irAEs require prompt diagnosis and treatment to avoid the occurrence of potential life-threatening complications. Therefore, it is imperative that emergency medicine providers are familiar with best practices for diagnosis and management of irAEs. In this activity, a multidisciplinary expert panel provides discussion, evaluation, and guidance for the effective diagnosis, treatment, and management of irAEs in patients with cancer.

CME Information

page 1 of 6